STOPPING MS IN ITS TRACKS, RESTORING LOST FUNCTION, ENDING MS FOREVER

New therapies showing positive results — Several late-stage, phase III clinical trials in relapsing MS are making their way toward seeking marketing approval. These include oral teriflunomide, oral BG-12, and intravenous alemtuzumab. An application was accepted by the FDA to review teriflunomide for marketing approval.

Speeding diagnosis – An international panel revised and simplified the “McDonald Criteria” commonly used to diagnose MS, which is expected to reduce the emotionally wrenching wait for a confirmed answer to possible MS symptoms.

Early results support research of parasitic worms to treat MS — At least two published studies reported results related to parasitic worms, called helminths, and their possible implications for treating MS. Further study, including the second phase of the clinical trial supported by the National MS Society, should determine whether a “probiotic” treatment approach using relatively harmless parasitic worms to alter immune activity will benefit people with MS.

MUCH more to read.  CONTINUE by clicking here